Citations

Clear

1792 citation(s) found for "Stephanie".

ypTNM versus pTNM staging after neoadjuvant therapy in rectal cancer
Miyakawa, Teppei , Lie, J T , Hu, Chung-Yuan, Ochiai, Kentaro , Behman, Ramy , Keeling, Stephanie , Shi, Qian , Nagtegaal, Irıs D. , Goldberg, Richard, Chang, George J. , Lie, Jessica J. , Shi, Qian , Nagtegaal, Iris D , Hu, Chung‐Yuan , Goldberg, Richard M.

Mayo Clinic

JNCI: Journal of the National Cancer Institute | June 16, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/jnci/djag192 | PMID 42308525 Get It

Abstract Background The tumor, node, metastasis (TNM) classification at pathological evaluation determines prognosis following cancer treatment. For rectal cancer patients undergoing neoadjuvant therapy, whether ypTNM likely confers different prognosis than pTNM. We compared survival outcomes of patients classified by ypTNM vs pTNM staging. Methods Patients with resected locoregional rectal cancer from the National Cancer Database who underwent upfront surgery (pTNM) and had ≥5 years follow-up (2010-2017) were compared with those receiving neoadjuvant therapy followed by surgery (ypTNM). To address treatment selection bias, analyses were stratified by receipt of guideline-concordant care. Overall survival (OS) was compared using Kaplan-Meier and multivariable Cox regression analyses. Results Of 50 436 patients (median age = 60; 61.4% male), 11 732 (23.3%) underwent upfront surgery and 38 704 (76.7%) received neoadjuvant therapy; 78.8% of the upfront surgery group received guideline-concordant care. In analyses stratified by guideline-concordant care, overall survival was similar for stage 0-I (hazard ratio [HR] = 1.05; 95% CI = 0.96 to 1.15) but significantly worse for ypTNM vs pTNM in stage II (HR = 1.50; 95% CI = 1.27 to 1.77; 5-year OS = 75.6% vs 83.2%) and stage III (HR = 1.60; 95% CI = 1.46 to 1.75; 5-year OS = 67.0% vs 78.2%). Multivariable analysis confirmed ypTNM was associated with worse survival at each stage (stage 0-I: HR = 1.14, P = .004; stage II: HR = 1.49, P < .001; stage III: HR = 1.60, P < .001). Conclusion Stage for stage, ypTNM classification is associated with worse survival than pTNM classification, with increasing difference at higher stages. Future staging systems and management guidelines should account for these differences to optimize prognostication and stratification for clinical trials and surveillance strategies.
Sex, Not Age, Predicts Weight Loss Outcomes With Tirzepatide: A Retrospective Analysis
Castaneda, Regina , Bechenati, Dima , Espinosa, Maria A., Villamarin, Jose L. , Tama, Elif , Safwan, Nancy , Fansa, Sima , Verastegui, Alfredo , McNally, Allyson W, Meek, Jesse L., Rajjo, Tamim , Shufelt, Chrisandra , Bechenati, Dima , Rivera Gutierrez, Rene de J , Espinosa, Maria A , Villamarin, Jose , Tama, Elif , Safwan, Nancy , Fansa, Sima , Verastegui, Alfredo , McNally, Allyson W , Mara, Kristin C , Winham, Stacey J , Rajjo, Tamim I , Acosta, Andres , Faubion, Stephanie S , Shufelt, Chrisandra L , Hurtado, Maria Daniela , Castaneda, Regina , Gutiérrez, René de Jesús Rivera , Mara, Kristin C. , Winham, Stacey J. , Acosta, Andrés , Faubion, Stephanie S. , Hurtado, Maria D.

Mayo Clinic

Obesity | June 15, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/oby.70231 | PMID 42290037 Get It

ABSTRACT Objective This study assessed the impact of sex and age on weight loss outcomes in patients receiving tirzepatide in real‐world clinical practice. Methods We conducted a retrospective cohort study of adults with overweight or obesity who initiated tirzepatide at Mayo Clinic between June 2022 and May 2024 and completed ≥ 12 months of continuous therapy. Primary outcome was total body weight loss percentage (TBWL%) at 15 months, stratified by sex and age groups (≤ 45, 46–59, ≥ 60 years). Results Among 1039 patients (57% women; mean age 56 ± 11 years), women achieved significantly greater TBWL% than men after 15 months of treatment (15.1% vs. 10.7%, p < 0.001). Patients aged ≤ 45 years had greater weight loss than those ≥ 60 years (15.1% vs. 12.3%, p = 0.024). In multivariable analyses, greater weight loss was independently associated with female sex, absence of type 2 diabetes, no prior obesity medication use, no concomitant weight gain‐promoting medications, and higher tirzepatide dosage. Age was not an independent predictor. Conclusions Sex, but not age, predicted weight loss with tirzepatide among individuals using the medication continuously for ≥ 12 months. These findings underscore the importance of incorporating sex‐specific considerations into personalized obesity treatment strategies.
Performance of large language models as an information resource on functional hypothalamic amenorrhea for patients and healthcare professionals
Safwan, Nancy , Karam, Jana, Berga, Sarah L. , Andrade, Maria D. Hurtado, Cole, Kristin, Faubion, Stephanie S., Shufelt, Chrisandra , Hurtado Andrade, Maria D, Shufelt, Chrisandra L , Karam, Jana, Winham, Stacey J. , Faubion, Stephanie S.

Mayo Clinic

Frontiers in Artificial Intelligence | June 15, 2026 | Volume: 9 | Issue: No issue available | Pages: No page available

10.3389/frai.2026.1788928 | PMID 42376443 Get It

Introduction To assess and compare the accuracy, readability, and overall performance of large language models (LLMs) in answering questions about functional hypothalamic amenorrhea (FHA) for patients and healthcare professionals. Methods A total of 11 patient-level and 15 clinician-level FHA-related questions were entered separately into four LLMs: ChatGPT 3.5 (free version), ChatGPT 4.0 (updated, paid subscription), Gemini, and OpenEvidence. OpenEvidence was used only for clinician-based questions. Responses were evaluated by three expert reviewers blinded to the LLM used who rated them as accurate and complete, accurate but incomplete, or inaccurate. A fourth reviewer resolved discordant scores. Readability for patient-level questions was assessed using the Flesch Reading Ease Score (FRES) and word count. Lower FRES scores indicate more difficult reading. Accuracy and completeness were compared using odds ratios (95% CI) with ChatGPT 3.5 as the reference model, and differences in readability were analyzed using Friedman’s test. Results LLM performance varied across question types. For patient-level questions, ChatGPT 4.0 achieved the highest accuracy (9 of 11; 82%), followed by ChatGPT 3.5 and Gemini (each 8 of 11; 73%), with no statistically significant differences. Among clinician-level questions, OpenEvidence demonstrated perfect accuracy (15 of 15; 100%), compared with 93% for and 80% for ChatGPT 4.0 and Gemini. Completeness followed similar patterns, with OpenEvidence providing the most complete clinician responses (93%) and ChatGPT 4.0 the most complete patient-level responses (89%). Readability differed significantly among models ( p = 0.012), with Gemini producing the most readable patient-level content (median FRES 43.5 [IQR 36.8–53.4]) compared with ChatGPT 3.5 (30.6 [16.8–48.4]) and ChatGPT 4.0 (28.8 [22.1–37.6]). Word counts did not differ significantly ( p = 0.39). Discussion LLMs demonstrated good overall performance in answering FHA-related questions but often provided incorrect or incomplete information. Fine tuning field-specific data, engineered prompts, and obtaining human-in-the-loop feedback may help improve the accuracy of these models.
Treatment of Headache with Occipital Nerve Blocks: Comparison Trial of Anesthetic with or Without Dexamethasone (P6-15.016)
Steel, Stephanie, Stern, Jennifer, Whealy, Mark, Cutrer, Michael, Kissoon, Narayan, Robertson, Carrie, Steel, Stephanie J., Stern, Jennifer I. , Whealy, Mark , Burke, Krista , Chiang, Chia‐Chun

Mayo Clinic

Neurology | June 10, 2026 | Volume: 106 | Issue: 11_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000216592 Get It

Donor-specific transplant outcomes from BMT CTN 1702: a multicenter prospective biologic assignment trial
Bashey, Asad, Logan, Brent R, Hill, LaQuisa C. , Symons, Heather J. , Farhadfar, Nosha , Grunwald, Michael R. , Pidala, Joseph A. , Dehn, Jason , Brunstein, Claudio, Arai, Sally , Leifer, Eric, He, Naya, Shaw, Bronwen E., Uberti, Joseph, Westervelt, Peter, Srour, Samer A, Pusic, Iskra , Vasu, Sumithira, Hayes‐Lattin, Brandon , Ciurea, Stefan O. , Horowitz, Mary M, Hill, LaQuisa C , Dehn, Jason G , Brunstein, Claudio , Juckett, Mark , Devine, Steven , Pusic, Iskra , Hayes-Lattin, Brandon , Ciurea, Stefan O , Lee, Stephanie J , Hogan, William J , Grunwald, Michael , Logan, Brent R. , Brunstein, Claudio G. , Shaw, Bronwen E. , Devine, Steven M. , Uberti, Joseph P., Srour, Samer A. , Vasu, Sumithira , Horowitz, Mary M. , Lee, Stephanie J. , Hogan, William J.

Mayo Clinic

Blood Advances | June 9, 2026 | Volume: 10 | Issue: 16 | Pages: 5543-5552

10.1182/bloodadvances.2026020355 | PMID 42263667 Get It

Abstract Newer approaches to control alloreactivity may produce similar transplant outcomes using HLA-mismatched donors vs HLA-matched unrelated donors (MUD). However, prospective comparisons are lacking. BMT CTN 1702 used a donor search prognosis score to assign patients to an 8/8 HLA MUD or the center’s preference of haploidentical related donors (HAPLO), mismatched unrelated donors (MMUD), or umbilical cord blood (UCB). Outcomes of MUD were compared to HAPLO, MMUD, and UCB transplantation after adjusting for covariates. Patients (n = 1179 [93% adults]) underwent transplantation with MUD (n = 772), HAPLO (n = 254), MMUD (n = 112), and UCB (n = 41) at a median of 3.7, 3.4, 3.9, and 3.8 months from enrollment. Posttransplant cyclophosphamide (PTCy) was used in 23.9%, 83.9%, 65.2%, and 0% of MUD, HAPLO, MMUD, and UCB. In multivariate analyses, compared to MUD, survival was lower for UCB (hazard ratio [HR], 2.65; P&lt; .001) but not statistically different for HAPLO and MMUD (HRs, 1.08 and 1.18, respectively). Relapse risk was not significantly different by donor, but treatment-related mortality (HR, 3.31; P&lt; .001) and disease-free survival (HR, 1.99; P = .002) were inferior for UCB but not different for HAPLO and MMUD than MUD. In patients who received PTCy, HAPLO and MMUD were associated with increased grade 3 or 4 acute graft-versus-host disease (GVHD; HR, 2.39 [P = .017] and 2.53 [P = .038], respectively) and chronic GVHD (HR, 1.71 for both; P = .028 and .080) than MUD, but other outcomes were not different. HAPLO or MMUD may be used to expedite transplantation when finding MUD is unlikely. This study was registered at www.clinicaltrials.gov as NCT03904134.
p21-senescent cells drive pancreatic islet dysfunction through targetable paracrine signaling in type 2 diabetes
Iwasaki, Kanako , Abarca, Cristian , Hela, Francesko , Sanjines, Stephanie, Pena, Sebastian, Le, Sandra, Pan, Hui , Jackson, Maya, Cahill, Christopher, Midha, Ayush, Baker, Dylan, Espinoza, Sara , Pena, Alejandro , Cigarroa, Francisco , Woodworth, Jillian L., Chuang, Jeffrey H., Kirkland, James L., Tchkonia, Tamara, Musi, Nicolas , Robson, Paul , Aguayo‐Mazzucato, Cristina , Iwasaki, Kanako , Robson, Paul , Aguayo-Mazzucato, Cristina , Pan, Hui , Pena, Alejandro , Carapeto, Priscila , Midha, Ayush , Alcoforado Diniz, Juliana , Domanskyi, Sergii , Espinoza, Sara, Chuang, Jeffrey H , Garovic, Vesna D. , Kirkland, James L. , Tchkonia, Tamar , Kuchel, George A.

Mayo Clinic

JCI Insight | June 9, 2026 | Volume: 11 | Issue: 14 | Pages: No page available

10.1172/jci.insight.197310 | PMID 42262869 Get It

Cellular senescence is an irreversible stress response, which leads to loss of cellular function and remodeling of the cellular secretory profile. In humans, pancreatic β cells undergo cellular senescence during the progression to type 2 diabetes (T2D). However, the mechanism linking β cell senescence to islet dysfunction remains unknown, and thus the therapeutic potential of targeting senescent cells in T2D is not established. Herein, we identified a subpopulation of senescent β cells expressing p21, which emerged early in the progression of T2D in humans and mice. Spatial transcriptomics and proteomics analyses confirmed senescence and loss of cellular identity in this subpopulation in humans. Functional analysis revealed lack of glucose responsiveness, high basal insulin secretion, and transcription of senescence-associated secretory phenotype (SASP) factors. SASP factors from p21 + β cells induced secondary senescence in neighboring cells, characterized by dysfunction and loss of identity. JAK inhibitors counteracted the induction of secondary senescence and restored β cell function in islets from humans with T2D and in mice fed a high-fat diet. These findings reveal the critical role of p21 + β cells in T2D pathogenesis and the therapeutic potential of targeting this pathophysiological process.